Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Karim, Rezaul ^a   Meyers, Craig ^b   Backendorf, Claude ^c   Ludigs, Kristina ^a,e   Offringa, Rienk ^a,f   van Ommen, Gert Jan B ^a   Melief, Cornelis J M ^a   van der Burg, Sjoerd H ^a   Boer, Judith M ^a,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

^d NETHERLANDS BIOINFORMATICS CENTRE   (Netherlands)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; CXCL11 CHEMOKINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA DIRECTED RNA POLYMERASE III; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INFLAMMASOME; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PROLINE RICH PROTEIN; PROTEIN KINASE R; RANTES; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSFORMING GROWTH FACTOR ALPHA; AUTACOID; POLYINOSINIC POLYCYTIDYLIC ACID; VIRUS RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEREGULATION; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INNATE IMMUNITY; KERATINOCYTE; PERSISTENT VIRUS INFECTION; PREPUCE; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WART VIRUS; ANIMAL; CELL CULTURE; DRUG EFFECT; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MOUSE; PAPILLOMA VIRUS; PHYSIOLOGY; UPREGULATION; VIROLOGY; VIRUS GENE;

HUMAN PAPILLOMAVIRUS;

ANIMALS; CELLS, CULTURED; CHEMOTAXIS; DOWN-REGULATION; GENE REGULATORY NETWORKS; GENES, VIRAL; HUMANS; INFLAMMASOMES; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; KERATINOCYTES; MICE; PAPILLOMAVIRIDAE; POLY I-C; RECEPTORS, VIRUS; UP-REGULATION;

EID: 79952687026     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017848     Document Type: Article

References (64)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
2. zur Hausen H, (2009) Papillomaviruses in the causation of human cancers- a brief historical account. Virology 384: 260-265.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, et al. (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802.
4. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, et al. (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12: 485-490.
5. Tindle RW, (2002) Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2: 59-65.
6. Stanley M, (2006) Immune responses to human papillomavirus. Vaccine 24 (Suppl 1): S16-S22.
7. Woo YL, Sterling J, Damay I, Coleman N, Crawford R, et al. (2008) Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG 115: 1616-1621.
8. van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, et al. (2005) Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 11: 5273-5280.
9. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, et al. (2004) Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64: 5449-5455.
10. de Vos van Steenwijk P, Piersma SJ, Welters MJ, van der Hulst JM, Fleuren G, et al. (2008) Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response. Clin Cancer Res 14: 7188-7195.
11. Doorbar J, (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110: 525-541.
12. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, et al. (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178: 3186-3197.
13. Kalali BN, Kollisch G, Mages J, Muller T, Bauer S, et al. (2008) Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J Immunol 181: 2694-2704.
14. Mempel M, Voelcker V, Kollisch G, Plank C, Rad R, et al. (2003) Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 121: 1389-1396.
15. Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, et al. (2007) Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 127: 331-341.
16. Kollisch G, Kalali BN, Voelcker V, Wallich R, Behrendt H, et al. (2005) Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114: 531-541.
17. Andersen JM, Al-Khairy D, Ingalls RR, (2006) Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod 74: 824-831.
18. Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, et al. (2004) The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 199: 1641-1650.
19. Lemaire PA, Lary J, Cole JL, (2005) Mechanism of PKR activation: dimerization and kinase activation in the absence of double-stranded RNA. J Mol Biol 345: 81-90.
20. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, et al. (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314: 997-1001.
21. Sankar S, Chan H, Romanow WJ, Li J, Bates RJ, (2006) IKK-i signals through IRF3 and NFkappaB to mediate the production of inflammatory cytokines. Cell Signal 18: 982-993.
22. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, et al. (2005) Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175: 2851-2858.
23. zur Hausen H, (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.
24. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, et al. (2000) Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 275: 6764-6769.
25. Ronco LV, Karpova AY, Vidal M, Howley PM, (1998) Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 12: 2061-2072.
26. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, et al. (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 75: 4283-4296.
27. Chang YE, Laimins LA, (2000) Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 74: 4174-4182.
28. McLaughlin-Drubin ME, Christensen ND, Meyers C, (2004) Propagation, infection, and neutralization of authentic HPV16 virus. Virology 322: 213-219.
29. Meyers C, Mayer TJ, Ozbun MA, (1997) Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol 71: 7381-7386.
30. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, et al. (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314: 997-1001.
31. Chiu YH, Macmillan JB, Chen ZJ, (2009) RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138: 576-591.
32. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, et al. (2009) RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 10: 1065-1072.
33. Fischer DF, Gibbs S, van De Putte P, Backendorf C, (1996) Interdependent transcription control elements regulate the expression of the SPRR2A gene during keratinocyte terminal differentiation. Mol Cell Biol 16: 5365-5374.
34. Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR, (2004) Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 112: 428-436.
35. Cabral A, Voskamp P, Cleton-Jansen AM, South A, Nizetic D, et al. (2001) Structural organization and regulation of the small proline-rich family of cornified envelope precursors suggest a role in adaptive barrier function. J Biol Chem 276: 19231-19237.
36. Lin SM, Du P, Huber W, Kibbe WA, (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36: e11.
37. Du P, Kibbe WA, Lin SM, (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548.
38. Du P, Kibbe WA, Lin SM, (2007) nuID: a universal naming scheme of oligonucleotides for illumina, affymetrix, and other microarrays. Biol Direct 2: 16.
39. Smyth GK, (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and Computational Biology Solutions using R and Bioconductor New York Springer pp. 397-420.
40. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate- A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289-300.
41. Jelier R, Schuemie MJ, Veldhoven A, Dorssers LC, Jenster G, et al. (2008) Anni 2.0: a multipurpose text-mining tool for the life sciences. Genome Biol 9: R96.
42. Salomonis N, Hanspers K, Zambon AC, Vranizan K, Lawlor SC, et al. (2007) GenMAPP 2: new features and resources for pathway analysis. BMC Bioinformatics 8: 217.
43. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M, (2004) The KEGG resource for deciphering the genome. Nucleic Acids Res 32: D277-D280.
44. van Iersel MP, Kelder T, Pico AR, Hanspers K, Coort S, et al. (2008) Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics 9: 399.
45. Pico AR, Kelder T, van Iersel MP, Hanspers K, Conklin BR, et al. (2008) WikiPathways: pathway editing for the people. PLoS Biol 6: e184.
46. Hestand MS, van Galen M, Villerius MP, van Ommen GJ, den Dunnen JT, et al. (2008) CORE_TF: a user-friendly interface to identify evolutionary conserved transcription factor binding sites in sets of co-regulated genes. BMC Bioinformatics 9: 495.
47. Alibes A, Yankilevich P, Canada A, az-Uriarte R, (2007) IDconverter and IDClight: conversion and annotation of gene and protein IDs. BMC Bioinformatics 8: 9.
48. Pivarcsi A, Koreck A, Bodai L, Szell M, Szeg C, et al. (2004) Differentiation-regulated expression of Toll-like receptors 2 and 4 in HaCaT keratinocytes. Arch Dermatol Res 296: 120-124.
49. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, et al. (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6: 981-988.
50. Woodworth CD, Cheng S, Simpson S, Hamacher L, Chow LT, et al. (1992) Recombinant retroviruses encoding human papillomavirus type 18 E6 and E7 genes stimulate proliferation and delay differentiation of human keratinocytes early after infection. Oncogene 7: 619-626.
51. Harder J, Schroder JM, (2002) RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J Biol Chem 277: 46779-46784.
52. Zhang J, Dyer KD, Rosenberg HF, (2003) Human RNase 7: a new cationic ribonuclease of the RNase A superfamily. Nucleic Acids Res 31: 602-607.
53. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, et al. (2005) A network-based analysis of systemic inflammation in humans. Nature 437: 1032-1037.
54. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178.
55. Becker CE, O'Neill LA, (2007) Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin Immunopathol 29: 239-248.
56. Woo YL, van den Hende M, Sterling JC, Coleman N, Crawford RA, et al. (2010) A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer 126: 133-141.
57. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, et al. (2003) Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63: 636-641.
58. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, et al. (2002) Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62: 472-479.
59. O'Neill LA, Bowie AG, (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7: 353-364.
60. Petrilli V, Dostert C, Muruve DA, Tschopp J, (2007) The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 19: 615-622.
61. Huang SM, McCance DJ, (2002) Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol 76: 8710-8721.
62. Spitkovsky D, Hehner SP, Hofmann TG, Moller A, Schmitz ML, (2002) The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J Biol Chem 277: 25576-25582.
63. Barnard P, McMillan NA, (1999) The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 259: 305-313.
64. An J, Mo D, Liu H, Veena MS, Srivatsan ES, et al. (2008) Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell 14: 394-407.